Clinical trial Recruiting at 1 site Observational Ages 5 to 70

Using advanced imaging to study retinal disorders

Official title: Adaptive Optics Imaging in Retinal Disorders

Run by The Hospital for Sick Children · NCT05386134 · Data updated 2026-11-12

This study is testing a new imaging technology to see how it can help understand and track changes in the eyes of people with inherited and acquired retinal disorders.

Quick facts

Study typeObservational
Ages5 Years to 70 Years
SexAll
Enrollment200 (estimated)
SponsorThe Hospital for Sick Children
Academic / other
Locations1 site (Toronto, Ontario)
StatusRecruiting
StartedJune 13, 2022
Main results expectedJune 13, 2032
Study endsJune 13, 2033
Registry record updatedApril 28, 2026
Trial IDNCT05386134 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates include individuals aged 5 to 70 years diagnosed with well-documented inherited or acquired retinal diseases.

Probably not a fit

Patients with significant eye movement disorders or other conditions that prevent stable imaging may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to explore the underlying retinal abnormalities in patients with inherited and acquired retinal disorders using adaptive optics (AO) technology. Approximately 200 participants, including a control group, will be recruited to undergo detailed retinal imaging and assessments. The study will track changes in retinal structures before and after various treatments, helping to establish AO imaging as a potential outcome measure for these conditions. Participants will have follow-up visits at 6 months and 1 year to monitor their progress.

Why it matters

Potential benefit: If successful, this study could enhance the understanding of retinal disorders and improve treatment outcomes through better monitoring of retinal changes.

How similar studies have gone: Other studies utilizing adaptive optics imaging have shown promise in understanding retinal diseases, indicating potential for success in this approach.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

1. Consent provided
2. Aged 5 - 70 years
3. Diagnosed with well documented retinal disorder

Control group Inclusion Criteria:

1. Subjects aged 5 years - 70 years with normal eye examination.
2. Patients with strabismus and otherwise normal visual acuity and eye examination
3. Patients with unilateral eye diseases such as cataract, with a normal eye exam in the fellow eye.

Exclusion Criteria:

1. Inability of the subject to maintain a stable position while seated
2. Uncontrolled nystagmus, trembling or movements of the eyes or the head
3. Presence of cataract or any opacity in the front of the eye that obscures retinal imaging
4. Any general disease such neurological disease which could affect vision and the retina.
5. History of previous uveitis, glaucoma, previous intra-ocular surgery or photodynamic therapy
6. High refractive errors (\> +15D or \< -15D) that cannot be corrected by the adaptive optics system.
7. Patients who have a history of photosensitivity or take any medicine that cause photosensitivity as a side effect
8. Patients who are aphakic after cataract surgery

Where it's running

  • The Hospital for Sick Children
    Toronto, Ontario, Canada
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.